Because of the oncogenic nature of PIM kinases, there has been increasing interest in developing small-molecule inhibitors that directly target the adenosine triphosphate (ATP)-binding domain of PIM proteins for cancer treatment [72]. This evidence concerns the gene PIM1 and cancer.